At the news
? NEUTRALIMPACT 4/10 8-K/A filed Mar 19, 2026 at 06:03 ET
Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date of a prior filing. The amendment confirms a court order delaying the bench trial with Hetero USA, Inc. over FIRDAPSE patent validity from March 23, 2026 to May 18, 2026. No other changes were made.
- Amendment No. 1 to Form 8-K filed to correct a scrivener's error in the signature date of the original March 18, 2026 filing.
- District Court for the District of New Jersey delayed the bench trial in the patent litigation with Hetero USA, Inc. from March 23, 2026 to May 18, 2026.
- The litigation concerns the validity of Catalyst's Orange Book-listed patents for FIRDAPSE, which expire in 2032, 2034, and 2037.
- No other changes were made to the original filing; the delay does not reflect a ruling on the merits of the case.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access